Cocrystal Pharma, Inc. (NASDAQ:COCP) Forecasted to Post Q3 2024 Earnings of ($0.59) Per Share

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Equities researchers at Zacks Small Cap issued their Q3 2024 earnings per share estimates for Cocrystal Pharma in a research note issued to investors on Tuesday, April 23rd. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings per share of ($0.59) for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($2.18) per share. Zacks Small Cap also issued estimates for Cocrystal Pharma’s FY2026 earnings at ($2.58) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Cocrystal Pharma in a research note on Thursday, April 4th.

Cocrystal Pharma Trading Down 3.0 %

Shares of Cocrystal Pharma stock opened at $1.51 on Thursday. The firm has a market cap of $15.36 million, a P/E ratio of -0.76 and a beta of 1.34. Cocrystal Pharma has a 12 month low of $1.33 and a 12 month high of $3.29. The stock’s fifty day moving average price is $1.49 and its 200-day moving average price is $1.63.

Cocrystal Pharma (NASDAQ:COCP) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.13.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.